Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)’s share price traded up 3.5% during trading on Friday . The company traded as high as $14.40 and last traded at $14.17, with a volume of 61,023 shares traded. The stock had previously closed at $13.69.

A number of equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 30th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and set a $24.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 17th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $25.00.

The company’s market cap is $251.97 million. The stock’s 50 day moving average price is $12.82 and its 200-day moving average price is $13.16.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.07. On average, analysts anticipate that Syndax Pharmaceuticals Inc. will post ($3.01) earnings per share for the current fiscal year.

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Syndax is developing entinostat with a focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.